Stromedix's Acquisition

Stromedix was acquired by Biogen on February 14, 2012.

Stromedix is a development stage biotechnology company focused on therapies for fibrosis. In February 2012, Stromedix was acquired by Biogen Idec. The valuation of Stromedix was $562.5 million.…

Articles about Stromedix's Acquisition: